Global Hemophilia Market Report: 2015 Edition – New Report by Koncept Analytics

DELHI, India - May 19, 2015 - PRLog -- Globally, the administration of coagulation factors depending upon the hemophilia type has become a preferred approach for treating hemophiliacs. Prophylaxis regimens not only reduce the average number of annual bleeds, but also reduce the likelihood of permanent and disabling joint damage. When a user goes from on-demand to prophylactic treatment, the product volume used increases several-fold and the number of bleeding episodes drops significantly. In countries where prophylactic treatment has become standard, Sweden being one example, the factor VIII and IX volumes used by each user are around double those in countries where prophylactic use has yet to become standard. As of 2014, fewer than 10% of patients receive routine prophylactic treatment.

Introduction of long-acting factors is expected to drive increased use of prophylactic treatment. A longer-acting recombinant factor VIII (rFVIII) molecule for the treatment of hemophilia A is witnessing an increasing competition on the horizon. The potential doubling in the number of players within the recombinant factor space is huge over the next five years, with a number of new entrants entering the recombinant space including Novo Nordisk, Biogen Idec, Octapharma and Green Cross.

As per the report “Global Hemophilia Market Report: 2015 Edition” by Koncept Analytics, the growth in hemophilia industry is driven by rising male population, global healthcare expense and increased rate of diagnosis and treatment among others. Higher rate of diagnosis, increasing number of patients and a rising share of patients receiving prophylactic treatment increases the usage of drugs by 2-3 times. A product mix change with a higher share of recombinant factor drugs is also a potential growth driver. Also, the FDA encourages the development of treatments for rare diseases by allowing a drug company to apply for orphan drug status. The patents and orphan drug periods of exclusivity on factor has allowed for the development of generic forms of factor concentrates, called biosimilars.

Hemophilia is an inherited or acquired bleeding disorder that prevents blood from clotting. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. Clotting factor is a protein in blood that controls bleeding. Without treatment, uncontrolled internal bleeding can cause stiffness, pain, severe joint damage and even death. People with hemophilia do not bleed any faster than normal, but they can bleed for a longer time. Their blood does not have enough clotting factor. Depending upon the coagulation factor deficiency, there are different types of hemophilia: Hemophilia A, Hemophilia B, Hemophilia with Inhibitor and Von Willebrand Disease.

It also encompasses a number of factors encouraging the growth of the global hemophilia market coupled with recent trends, developments and challenges hindering the growth of the industry. The company profile section of the report covers detailed description of the players operating in the global hemophilia market along with in-depth analysis of regional competition among the major players. By deploying SPSS Inc.’s data integration and analysis capabilities, future growth prediction in terms of value of the global hemophilia market has also been analyzed in the report.

List of Charts

Types of Hemophilia
Global Hemophilia Market Value (2010-2014E)
Hemophilia Market by Segments (2014E)
Hemophilia Patients by Type (2014)
Hemophilia Patients by Severity (2014)
Global Hemophilia A Market Value (2011-2016E)
Hemophilia A Patients Treated Per Year Globally (2010-2017E)
Hemophilia A Patients Receiving Treatment by Region (2014E)
Global Demand for Factor VIII (2010-2016E)
Global Demand for Factor VIII by Type (2014E)
Global Supply/Demand of Recombinant FVIII (2010-2016E)
Global Hemophilia B Market Value (2011-2016E)
Hemophilia B Patients Treated Per Year Globally (2014E-2020E)
Global Hemophilia A & B with Inhibitors Market Value (2011-2016E)
Global Von Willebrand Disease Market Value (2011-2016E)
Hemophilia Patients in US (2013-2018E)
Hemophilia B Patients Treated Per Year in US (2014E-2020E)
Recombinant Factor VIII Market Share in Australia (2010-2014)
Hemophilia A Patients Receiving Treatment in Europe (2010-2017E)
Low Diagnosis and Treatment Rates of Hemophilia (2014)
Global Male Population (2010-2014)
Global Health Care Expenditure Per Capita (2009-2014E)
Adoption of Prophylactic Treatment across Countries
Annual Switching Rates
Hemophilia A Market Share by Company (2014)
Hemophilia B Market Share by Company (2014)
Recombinant FVIII Market Share by Company (2013)
Recombinant FVIII Market Share in US by Company (2013E)
Baxter's Revenue Share by Segments (2014)
Baxter's Net Sales and Net Income (2010-2014)
Novo Nordisk's Revenue Share by Segments (2014)
Novo Nordisk's Net Sales and Net Income (2010-2014)
Pfizer's Revenue Share by Segments (2014)
Pfizer's Net Sales and Net Income (2010-2014)
Global Hemophilia Market Forecast (2014-2018F)

List of Tables

Incidence of Hemophilia in Global Terms (2013)
US Hemophilia Market Size (2014E)
Number of People in the Registry and Treated by Broad Diagnosis
European Hemophilia Market Size (2014E)
Players and Products across the Different Hemophilia Types (2014)
New Products under Development or Recently Approved
US Factor Products on Market (2014)
Novo Nordisk’s Hemophilia Portfolio
Dependent & Independent Variables (2010-2014)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output

Note:  Purchase by Section Also Available

For more Information:

http://www.konceptanalytics.com/Researchreport/global-hemophilia-market-report-2015-edition-197.aspx

Koncept Analytics

Vikas Gupta

(Business Development Manager)

FFCS-36, Ansal Plaza

Vaishali, Ghaziabad

U.P - 201010

Tele: +91-120-4130959

Mobile: +91-9811715635

Mail ID – vikas@konceptanalytics.com

Koncept Analytics is a market research company. We are in the field of Market Research from last 10 Years. We do research in telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, food & beverages and media sectors. For more information:

http://www.konceptanalytics.com